Rigel Pharmaceuticals, Inc. (RIGL), Thursday announced that it has agreed to acquire the U.S. rights to Gavreto from Blueprint Medicines Corp. for an initial payment of $10 million, followed by an additional $5 million after one year of the closing date.
Blueprint Medicines Corp. found a new U.S. commercialization home for Gavreto (pralsetinib) through an agreement with Rigel Pharmaceuticals Inc. potentially worth $117.5 million, now that Roche Holding AG has relinquished all rights.
Knight Therapeutics Announces Regulatory Submission of Fostamatinib in Brazil streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
MONTREAL, Feb. 21, 2024 Knight Therapeutics Inc., a pan-American specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has submitted a.